FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma
Invectys announces U.S. Food and Drug Administration (FDA) has granted Fast Track designation to IVS-3001, its cutting-edge CAR-T cell immunotherapy targeting the rarely exploited immune checkpoint and tumor-specific antigen HLA-G.
Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership
Invectys announces it has initiated the clinical trial of its lead CAR-T program, IVS-3001, in solid tumors, as well as the appointment of Dr. Jake Kushner, M.D., as its new CEO.
Invectys to participate in project Melomanes
Melomanes is a multidisciplinary project, which aims to develop a novel combination treatment for metastatic melanoma, based on nanoparticles and CAR-T cells.
Invectys and CTMC Announce FDA Clearance of IND Application for Anti-HLA-G CAR-T Cell Therapy
FDA granted IND clearance for a Phase 1/2a clinical trial for IVS-3001, Invectys’s lead engineered anti-HLA–G CAR-T cell therapy, for the treatment of patients with solid tumors.
Invectys, MD Anderson and CTMC Announce Strategic Collaboration for CAR T Cell Therapy Development
The collaboration will build upon the HLA-G platform pioneered by Invectys to advance novel CAR T cell therapies through preclinical development with CTMC into early-phase clinical studies at MD Anderson, and bring Invectys’ technology together with the cell therapy development and manufacturing expertise of CTMC and the clinical trials expertise of MD Anderson.
Invectys, Inc. Appoints François Lescure as General Manager of its R&D Subsidiary, Invectys, SAS
Founder of MédecinDirect and former Manager of Teladoc France, Dr. Lescure is a veteran of the healthcare industry with a career spawning over more than 30 years.
Wayne A. Marasco, M.D., Ph.D. joins Invectys’ Scientific Advisory Board
Dr. Marasco brings to Invectys his pioneering expertise in the field of human antibody engineering and cellular/stem cell therapies in which he is senior author of over 175 peer reviewed publications, chapters, books and monographs and holds over 75 patents.
Invectys appoints Jian Cao, Ph.D., as Vice President, Pharmaceutical Development
Dr. Cao brings in extensive experience in biological drug development and GMP manufacturing support of IND through BLA submissions.
Invectys to Provide 2022 Business Outlook at the H.C. Wainwright Bioconnect Virtual Conference, January 10-13, 2022
Praveen Tyle, Ph.D., Invectys Inc. President and CEO will provide an outlook for the business and its pipeline of treatments for cancer diseases and present an overview of all of Invectys’ projects to date on January 10th.
Invectys Inc. to participate in the 2022 JP Morgan Healthcare Meeting and Biotech Showcase, January 10-19, 2022
Praveen Tyle, Ph.D., Invectys Inc. President and CEO will participate in the JP Morgan Healthcare Meeting and Biotech showcase held virtually on January 10-19, 2022.
Invectys Inc. to participate in the 2021 Roth Virtual Healthcare Private Company Forum on June 28th, 2021
Praveen Tyle, Ph.D., Invectys Inc. President and CEO, and Julien Caumartin, Ph.D. CSO of Invectys SA, will participate in the Roth Virtual Healthcare Private Company Forum, on Monday, June 28th, 2021.
June, 1st, 2021 – Invectys, Inc appoints Rosemary Williams, CPA as Vice-President for Administration and Controller
Invectys Inc. annouces the nomination of Rosemary Williams, CPA as Vice-President for Administration and Controller.
May, 4, 2021 – Invectys, Inc appoints Biopharma Veteran, Praveen Tyle, PhD as President & CEO
Invectys Inc. annouces the nomination of Praveen Tyle, veteran biopharma manager, as its new CEO.
Nov, 12, 2020 – Invectys’ CARGo project garners $14.2M 2020 CPRIT Award (Cancer Prevention and Research Institute of Texas )
Invectys’ anti-HLA-G CAR-T cell project was awarded with the CPRIT Award, through which it has garnered $14.2 million.
May, 5, 2020 – Invectys: Dennis J. Purcell (Aisling Capital) join Advisory Board
Invectys Strengthens Advisory Board with the Appointment of Dennis J. Purcell, Life Sciences Industry Veteran and Founder of Aisling Capital LLC.
Feb, 4, 2020 – Invectys reports in vivo efficacy of its pan anti-tumor anti-HLA-G CAR-T cells
These results could lead to CAR-T cells more potent against solid tumors.
Jun, 18, 2019 – Invectys élu « meilleur projet – jeune entreprise » 2019 par le Board international de MATWIN
Invectys est le lauréat 2019 du prix industriel du programme MATWIN de soutien à la maturation de projets innovants en oncologie.